Theratechnologies, Inc (THTX) - מקדם חוב לטווח ארוך להון

Theratechnologies Inc. (THTX) production facilities in North America focus on HIV therapies and cancer research. This price chart illustrating trading dynamics shows a value of 0.00. The current price is based on the decision to forgo mergers in favor of debt repayment and growth in sales of legacy drugs. High R&D costs and strict FDA oversight protect the firm's position from the emergence of cheap generics.

This ratio determines financial stability by comparing long-term borrowings to equity to assess the business's degree of dependence on external lending. An analysis of the long-term debt-to-equity ratio for Theratechnologies Inc. (THTX) confirms the effectiveness of its manufacturing outsourcing model, which minimizes capital expenditures on equipment, thereby reducing the debt load and enhancing the investment security of the asset.